Copyright 2026 All rights reserved.

Business area

bHLBIO develops the innovative drug for the healthy human life, using our novel CUPID platform
which can monitor in real time the Protein-Protein Interaction (PPI) in living cell.

REV3-REV7

Target of Drug Resistans

PPI Target for
Oxaliplatin-resistance
(Chemoresistance)

  • No FDA-approved drug available
  • Trget : REV3-REV7-REV1
  • Cause the first-line chemotherapy problem in various cancer types

Leadable Hit for Drug Resistance

p57 peptide (live in cell studies)


Experimental results of the resistance-overcoming effect of p57
Overexpression of REV 3/7 in HEK 293T cells
▶ Trigger of resistance to oxaliplatin confirmed
It was confirmed that resistance to oxaliplatin triggered by overexpression of REV 3/7 can be overcome by co-expression of p57.